Table of Content

1 INTRODUCTION (Page No. - 34)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY CONSIDERED 
    1.4 STAKEHOLDERS 
    1.5 LIMITATIONS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 39)
    2.1 RESEARCH APPROACH 
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    2.3 MARKET GROWTH RATE PROJECTIONS 
    2.4 DATA TRIANGULATION AND METHODOLOGY APPROACH 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
3 EXECUTIVE SUMMARY (Page No. - 53)
4 PREMIUM INSIGHTS (Page No. - 59)
    4.1 RESEARCH ANTIBODIES AND REAGENTS MARKET OVERVIEW 
    4.2 RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY APPLICATION 
    4.3 GEOGRAPHIC GROWTH OPPORTUNITIES 
    4.4 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 
    4.5 RESEARCH ANTIBODIES AND REAGENTS MARKET:  DEVELOPED VS. EMERGING MARKETS 
5 MARKET OVERVIEW (Page No. - 63)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
                    5.2.1.1 Rising funding for life sciences research
                    5.2.1.2 Increasing industry-academia collaborations
                    5.2.1.3 Growing applications of biomarker identification & validation
           5.2.2 RESTRAINTS
                    5.2.2.1 Quality concerns and inadequacy of reproducible results
                    5.2.2.2 Ethical concerns for animal welfare in antibody production
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High-growth potential of emerging economies
                    5.2.3.2 Personalized medicine and protein therapeutics
                    5.2.3.3 Growth in stem cell and neurobiology research
                    5.2.3.4 Outsourcing services to CROs
           5.2.4 CHALLENGES
                    5.2.4.1 Complexities associated with antibody development
                    5.2.4.2 Increasing pricing pressure
    5.3 INDUSTRY TRENDS 
           5.3.1 GROWING R&D ON THERAPEUTIC ANTIBODIES
           5.3.2 OPTIMAL USAGE OF RECOMBINANT ANTIBODIES
    5.4 SUPPLY CHAIN ANALYSIS 
    5.5 PRODUCT PORTFOLIO ANALYSIS 
    5.6 TECHNOLOGY ANALYSIS 
    5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.8 PRICING ANALYSIS 
           5.8.1 INDICATIVE PRICING ANALYSIS, BY ANTIBODIES
           5.8.2 INDICATIVE PRICING ANALYSIS OF OVERALL MARKET  (QUALITATIVE ANALYSIS)
    5.9 TRADE ANALYSIS (HS CODES) 
    5.10 ECOSYSTEM ANALYSIS 
           5.10.1 ROLE IN ECOSYSTEM
    5.11 PATENT ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS 
    5.13 REGULATORY ANALYSIS 
           5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.14 PORTER’S FIVE FORCES ANALYSIS 
           5.14.1 THREAT OF NEW ENTRANTS
           5.14.2 THREAT OF SUBSTITUTES
           5.14.3 BARGAINING POWER OF SUPPLIERS
           5.14.4 BARGAINING POWER OF BUYERS
           5.14.5 INTENSITY OF COMPETITIVE RIVALRY
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
6 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT (Page No. - 89)
    6.1 INTRODUCTION 
    6.2 REAGENTS 
           6.2.1 MEDIA & SERA
                    6.2.1.1 Critical component in cell culture to boost demand
           6.2.2 STAINS & DYES
                    6.2.2.1 Growing applications in cell biology and molecular studies to fuel uptake
           6.2.3 FIXATIVES
                    6.2.3.1 High utilization in immunohistochemistry and Western blotting to propel market
           6.2.4 BUFFERS
                    6.2.4.1 High utilization in drug development to drive market
           6.2.5 SOLVENTS
                    6.2.5.1 Broad applications in pharmaceutical processes and IHC assays to propel market
           6.2.6 ENZYMES
                    6.2.6.1 Rising proteomic & genomic research studies to fuel uptake
           6.2.7 PROBES
                    6.2.7.1 Quantitative and versatile capabilities to propel market
           6.2.8 OTHER REAGENTS
    6.3 ANTIBODIES 
           6.3.1 ANTIBODIES, BY TYPE
                    6.3.1.1 Primary antibodies
                               6.3.1.1.1 Rising demand for personalized therapeutics to drive market
                    6.3.1.2 Secondary antibodies
                               6.3.1.2.1 Low production costs to support market growth
           6.3.2 ANTIBODIES, BY FORM
                    6.3.2.1 Monoclonal antibodies
                               6.3.2.1.1 High usage in biomedical science to boost demand
                    6.3.2.2 Polyclonal antibodies
                               6.3.2.2.1 Ability to target specific assays to fuel uptake
                    6.3.2.3 Recombinant antibodies
                               6.3.2.3.1 High usage in cancer treatment to fuel uptake
           6.3.3 ANTIBODIES, BY SOURCE
                    6.3.3.1 Mice
                               6.3.3.1.1 Preferred hosts for antibody production to propel market
                    6.3.3.2 Rabbits
                               6.3.3.2.1 Cost-effective benefits to drive demand
                    6.3.3.3 Other sources
           6.3.4 ANTIBODIES, BY RESEARCH AREA
                    6.3.4.1 Oncology
                               6.3.4.1.1 Rising incidence of cancer and associated oncology diagnostics to drive market
                    6.3.4.2 Infectious diseases
                               6.3.4.2.1 Increasing incidence of viral infections to drive market
                    6.3.4.3 Immunology
                               6.3.4.3.1 Growing awareness of autoimmune diseases to support market growth
                    6.3.4.4 Neurobiology
                               6.3.4.4.1 Wide applications in molecular & cellular neuroscience to drive market
                    6.3.4.5 Stem cells
                               6.3.4.5.1 Growing importance of transplantations to propel market
                    6.3.4.6 Other research areas
7 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY (Page No. - 157)
    7.1 INTRODUCTION 
    7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
           7.2.1 ABILITY TO DETECT ONCOLOGY AND INFECTIOUS DISEASE SAMPLES TO PROPEL MARKET
    7.3 FLOW CYTOMETRY 
           7.3.1 GROWING APPLICATIONS IN CANCER RESEARCH TO DRIVE MARKET
    7.4 WESTERN BLOTTING 
           7.4.1 HIGH ACCURACY AND SIMPLIFIED ASSESSMENT TO DRIVE MARKET
    7.5 IMMUNOFLUORESCENCE 
           7.5.1 ABILITY TO DETERMINE SPECIFIC GENE EXPRESSIONS TO SUPPORT MARKET
    7.6 IMMUNOHISTOCHEMISTRY 
           7.6.1 GROWING APPLICATIONS IN DRUG EFFICACY TESTING TO SUPPORT MARKET GROWTH
    7.7 IMMUNOPRECIPITATION 
           7.7.1 HIGH-SPECIFICITY RESULTS TO CONTRIBUTE TO MARKET GROWTH
    7.8 OTHER TECHNOLOGIES 
8 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION (Page No. - 179)
    8.1 INTRODUCTION 
    8.2 PROTEOMICS 
           8.2.1 RISING GOVERNMENT INVESTMENTS IN RESEARCH PROJECTS TO DRIVE MARKET
    8.3 DRUG DEVELOPMENT 
           8.3.1 RISING PHARMA R&D EXPENDITURE TO PROPEL MARKET
    8.4 GENOMICS 
           8.4.1 INCREASING INVESTMENTS IN GENOMICS MEDICINE TO SUPPORT MARKET GROWTH
9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER (Page No. - 191)
    9.1 INTRODUCTION 
    9.2 RESEARCH LABORATORIES 
           9.2.1 INCREASING STUDIES IN BIOMEDICAL AND LIFE SCIENCE RESEARCH TO PROPEL MARKET
    9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.3.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
    9.4 CONTRACT RESEARCH ORGANIZATIONS 
           9.4.1 ASSISTED SERVICES FOR MAB DEVELOPMENT TO SUPPORT MARKET GROWTH
10 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION (Page No. - 201)
     10.1 INTRODUCTION 
     10.2 NORTH AMERICA 
             10.2.1 US
                        10.2.1.1 Increasing funding for oncology therapeutics to drive market
             10.2.2 CANADA
                        10.2.2.1 Rising funding for biomedical research projects to drive market
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             10.3.1 GERMANY
                        10.3.1.1 Growing industry-academia collaborations for life science research to drive market
             10.3.2 UK
                        10.3.2.1 Rising incidence of cancer to support market growth
             10.3.3 FRANCE
                        10.3.3.1 Rising demand for personalized therapeutics to support market growth
             10.3.4 ITALY
                        10.3.4.1 Federal funding for targeted research projects to support market growth
             10.3.5 SPAIN
                        10.3.5.1 Favorable funding initiatives for novel therapeutic development to propel market
             10.3.6 REST OF EUROPE
             10.3.7 EUROPE: RECESSION IMPACT
     10.4 ASIA PACIFIC 
             10.4.1 CHINA
                        10.4.1.1 Rising establishment of R&D facilities to propel market
             10.4.2 JAPAN
                        10.4.2.1 Rising growth in biotechnology industries to propel market
             10.4.3 INDIA
                        10.4.3.1 Rising growth in pharmaceutical industries to drive market
             10.4.4 REST OF ASIA PACIFIC
             10.4.5 ASIA PACIFIC: RECESSION IMPACT
     10.5 LATIN AMERICA 
             10.5.1 BRAZIL
                        10.5.1.1 Growing hub for pharma R&D to support market growth
             10.5.2 REST OF LATIN AMERICA
             10.5.3 LATIN AMERICA: RECESSION IMPACT
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 MIDDLE EAST
                        10.6.1.1 Rising research collaborations to drive market
             10.6.2 AFRICA
                        10.6.2.1 Growing genomic studies to support market growth
             10.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE (Page No. - 293)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
     11.3 MARKET SHARE ANALYSIS 
             11.3.1 RESEARCH ANTIBODIES AND REAGENTS MARKET: MARKET SHARE ANALYSIS
             11.3.2 RESEARCH ANTIBODIES MARKET: MARKET SHARE ANALYSIS (2022)
     11.4 REVENUE SHARE ANALYSIS OF TOP PLAYERS 
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
             11.5.5 COMPANY FOOTPRINT
                        11.5.5.1 Company footprint (25 Companies)
                        11.5.5.2 Company product footprint (25 Companies)
                        11.5.5.3 Company regional footprint (25 Companies)
     11.6 START-UP/SME EVALUATION MATRIX 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
     11.7 COMPETITIVE TRENDS 
12 COMPANY PROFILES (Page No. - 310)
     12.1 KEY PLAYERS 
             12.1.1 ABCAM PLC
                        12.1.1.1 Business overview
                        12.1.1.2 Products offered
                        12.1.1.3 Recent developments
                        12.1.1.4 MnM view
                                     12.1.1.4.1 Key strengths
                                     12.1.1.4.2 Strategic choices made
                                     12.1.1.4.3 Weaknesses and competitive threats
             12.1.2 CELL SIGNALING TECHNOLOGY, INC.
                        12.1.2.1 Business overview
                        12.1.2.2 Products offered
                        12.1.2.3 MnM view
                                     12.1.2.3.1 Key strengths
                                     12.1.2.3.2 Strategic choices made
                                     12.1.2.3.3 Weaknesses and competitive threats
             12.1.3 THERMO FISHER SCIENTIFIC INC.
                        12.1.3.1 Business overview
                        12.1.3.2 Products offered
                        12.1.3.3 Recent developments
                        12.1.3.4 MnM view
                                     12.1.3.4.1 Key strengths
                                     12.1.3.4.2 Strategic choices made
                                     12.1.3.4.3 Weaknesses and competitive threats
             12.1.4 MERCK KGAA
                        12.1.4.1 Business overview
                        12.1.4.2 Products offered
                        12.1.4.3 Recent developments
                        12.1.4.4 MnM view
                                     12.1.4.4.1 Key strengths
                                     12.1.4.4.2 Strategic choices made
                                     12.1.4.4.3 Weaknesses and competitive threats
             12.1.5 BD
                        12.1.5.1 Business overview
                        12.1.5.2 Products offered
                        12.1.5.3 Recent developments
                        12.1.5.4 MnM view
                                     12.1.5.4.1 Key strengths
                                     12.1.5.4.2 Strategic choices made
                                     12.1.5.4.3 Weaknesses and competitive threats
             12.1.6 BIO-RAD LABORATORIES, INC.
                        12.1.6.1 Business overview
                        12.1.6.2 Products offered
                        12.1.6.3 Recent developments
             12.1.7 F. HOFFMANN-LA ROCHE LTD.
                        12.1.7.1 Business overview
                        12.1.7.2 Products offered
                        12.1.7.3 Recent developments
             12.1.8 AGILENT TECHNOLOGIES, INC.
                        12.1.8.1 Business overview
                        12.1.8.2 Products offered
                        12.1.8.3 Recent developments
             12.1.9 DANAHER
                        12.1.9.1 Business overview
                        12.1.9.2 Products offered
                        12.1.9.3 Recent developments
             12.1.10 LONZA
                        12.1.10.1 Business overview
                        12.1.10.2 Products offered
                        12.1.10.3 Recent developments
             12.1.11 GENSCRIPT
                        12.1.11.1 Business overview
                        12.1.11.2 Products offered
                        12.1.11.3 Recent developments
             12.1.12 REVVITY
                        12.1.12.1 Business overview
                        12.1.12.2 Products offered
                        12.1.12.3 Recent developments
             12.1.13 ILLUMINA, INC.
                        12.1.13.1 Business overview
                        12.1.13.2 Products offered
                        12.1.13.3 Recent developments
     12.2 OTHER PLAYERS 
             12.2.1 IMMUNOPRECISE ANTIBODIES LTD.
             12.2.2 FUJIREBIO
             12.2.3 ANALYTIK JENA GMBH+CO. KG
             12.2.4 OMEGA BIO-TEK, INC.
             12.2.5 DOVETAIL GENOMICS
             12.2.6 ATLAS ANTIBODIES AB
             12.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
             12.2.8 SANTA CRUZ BIOTECHNOLOGY, INC.
             12.2.9 JACKSON IMMUNORESEARCH INC.
             12.2.10 PROTEINTECH GROUP, INC.
             12.2.11 ICL, INC.
             12.2.12 SOUTHERNBIOTECH
13 APPENDIX (Page No. - 376)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 
LIST OF TABLES (479 TABLES)
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2028 (USD MILLION)
TABLE 4 RESEARCH ANTIBODIES AND REAGENTS MARKET: IMPACT ANALYSIS
TABLE 5 RESEARCH ANTIBODIES AND REAGENTS MARKET: PRODUCT PORTFOLIO ANALYSIS
TABLE 6 INDICATIVE PRICING OF ANTIBODIES, BY KEY PLAYERS (2022)
TABLE 7 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS (HS CODE 3822),  2018–2022 (USD THOUSAND)
TABLE 8 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS (HS CODE 3822),  2018–2022 (USD THOUSAND)
TABLE 9 INDICATIVE LIST OF PATENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET
TABLE 10 RESEARCH ANTIBODIES AND REAGENTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024)
TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 RESEARCH ANTIBODIES AND REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 14 REAGENTS, BY TYPE AND APPLICATION
TABLE 15 RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 16 RESEARCH REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 18 EUROPE: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 22 RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY REGION,  2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 26 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY REGION,  2021–2028 (USD MILLION)
TABLE 29 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 EUROPE: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 31 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 32 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES,  BY REGION, 2021–2028 (USD MILLION)
TABLE 34 RESEARCH REAGENTS MARKET FOR FIXATIVES, BY REGION, 2021–2028 (USD MILLION)
TABLE 35 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 36 EUROPE: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 38 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 RESEARCH REAGENTS MARKET FOR BUFFERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 42 EUROPE: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 44 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 RESEARCH REAGENTS MARKET FOR SOLVENTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 48 EUROPE: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 50 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 RESEARCH REAGENTS MARKET FOR ENZYMES, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 54 EUROPE: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 56 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 RESEARCH REAGENTS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 60 EUROPE: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 62 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 OTHER RESEARCH REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 65 NORTH AMERICA: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 66 EUROPE: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 67 ASIA PACIFIC: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 68 LATIN AMERICA: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR OTHER RESEARCH REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 71 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 72 EUROPE: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 74 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 75 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 76 ANTIBODIES, BY TYPE AND APPLICATION
TABLE 77 RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 PRIMARY RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 80 EUROPE: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 82 LATIN AMERICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 83 MIDDLE EAST & AFRICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 SECONDARY RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 86 EUROPE: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 88 LATIN AMERICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ANTIBODIES, BY FORM AND APPLICATION
TABLE 91 RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 92 MONOCLONAL RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 93 NORTH AMERICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 94 EUROPE: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 96 LATIN AMERICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 POLYCLONAL RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 99 NORTH AMERICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 100 EUROPE: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 102 LATIN AMERICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 RECOMBINANT RESEARCH ANTIBODIES MARKET, BY REGION,  2021–2028 (USD MILLION)
TABLE 105 NORTH AMERICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 106 EUROPE: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 107 ASIA PACIFIC: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 108 LATIN AMERICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 ANTIBODIES, BY SOURCE AND APPLICATION
TABLE 111 RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 112 MICE ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 EUROPE: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 ASIA PACIFIC: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 LATIN AMERICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: MICE ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 118 RABBIT ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 119 NORTH AMERICA: RABBIT ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 120 EUROPE: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: RABBIT ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 124 OTHER ANTIBODY SOURCES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 125 NORTH AMERICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 126 EUROPE: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 ASIA PACIFIC: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 128 LATIN AMERICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 129 MIDDLE EAST & AFRICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 130 ANTIBODIES, BY RESEARCH AREA AND APPLICATION
TABLE 131 RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
TABLE 132 RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY REGION,  2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 134 EUROPE: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 136 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 138 RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
TABLE 139 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 EUROPE: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 142 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 143 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 144 RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY REGION,  2021–2028 (USD MILLION)
TABLE 145 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 EUROPE: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 147 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 148 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 149 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 150 RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY REGION,  2021–2028 (USD MILLION)
TABLE 151 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 152 EUROPE: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 153 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 154 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 155 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 156 RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY REGION,  2021–2028 (USD MILLION)
TABLE 157 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 158 EUROPE: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 159 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 160 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 162 RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY REGION,  2021–2028 (USD MILLION)
TABLE 163 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 164 EUROPE: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 166 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 167 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 168 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 169 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY REGION,  2021–2028 (USD MILLION)
TABLE 170 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 171 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 172 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 174 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 175 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY REGION, 2021–2028 (USD MILLION)
TABLE 176 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 177 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 180 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 181 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 182 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 183 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 185 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 187 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE,  BY REGION, 2021–2028 (USD MILLION)
TABLE 188 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 189 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 190 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 191 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 193 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,  BY REGION, 2021–2028 (USD MILLION)
TABLE 194 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 195 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 196 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 197 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION,  BY REGION, 2021–2028 (USD MILLION)
TABLE 200 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 201 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 202 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 203 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 204 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 205 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES,  BY REGION, 2021–2028 (USD MILLION)
TABLE 206 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 207 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 208 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 209 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 210 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 211 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 212 TECHNOLOGICAL APPLICATIONS OF ANTIBODIES IN PROTEOMICS
TABLE 213 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY REGION,  2021–2028 (USD MILLION)
TABLE 214 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 215 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 216 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 217 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 218 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 219 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
TABLE 220 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 221 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 222 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 223 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 224 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 225 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY REGION,  2021–2028 (USD MILLION)
TABLE 226 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 227 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 228 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 229 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS,  BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 230 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 231 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 232 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES,  BY REGION, 2021–2028 (USD MILLION)
TABLE 233 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 234 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 235 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 236 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 237 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 238 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 239 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 240 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 241 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 242 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 243 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 244 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 245 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 246 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 247 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 248 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 250 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION,  2021–2028 (USD MILLION)
TABLE 251 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 252 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 253 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 255 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM,  2021–2028 (USD MILLION)
TABLE 256 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 257 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 258 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 259 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 260 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 261 US NIH BUDGET FOR DISCIPLINES, FY 2019 TO FY 2022 (USD BILLION)
TABLE 262 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 263 US: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 264 US: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 265 US: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 266 US: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 267 US: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
TABLE 268 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 269 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 270 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 271 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 272 CANADA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 273 CANADA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 CANADA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 275 CANADA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 276 CANADA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 277 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 278 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 279 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 280 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 281 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 282 EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 283 EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 284 EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 285 EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 286 EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 287 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 288 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 289 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 290 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 291 GERMANY: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 292 GERMANY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 293 GERMANY: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 294 GERMANY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 295 GERMANY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 296 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 297 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 298 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 299 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 300 UK: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 301 UK: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 302 UK: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 303 UK: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 304 UK: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
TABLE 305 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 306 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 307 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 308 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 309 FRANCE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 310 FRANCE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 311 FRANCE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 312 FRANCE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 313 FRANCE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 314 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 315 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 316 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 317 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 318 ITALY: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 319 ITALY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 320 ITALY: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 321 ITALY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 322 ITALY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 323 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 324 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 325 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 326 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 327 SPAIN: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 328 SPAIN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 329 SPAIN: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 330 SPAIN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 331 SPAIN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 332 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 333 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 334 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 335 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 336 REST OF EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 337 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 338 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM,  2021–2028 (USD MILLION)
TABLE 339 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 340 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 341 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 342 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 343 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 344 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 345 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 346 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 347 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 348 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 349 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 350 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 351 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 352 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 353 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 354 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 355 CHINA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 356 CHINA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 357 CHINA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 358 CHINA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 359 CHINA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 360 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 361 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 362 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 363 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 364 JAPAN: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 365 JAPAN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 366 JAPAN: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 367 JAPAN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 368 JAPAN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 369 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 370 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 371 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 372 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 373 INDIA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 374 INDIA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 375 INDIA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 376 INDIA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 377 INDIA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 378 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 379 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 380 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 381 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 382 REST OF ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
TABLE 383 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
TABLE 384 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM,  2021–2028 (USD MILLION)
TABLE 385 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 386 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 387 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 388 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 389 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 390 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 391 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 392 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 393 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 394 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 395 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 396 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 397 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 398 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 399 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 400 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 401 BRAZIL: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 402 BRAZIL: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 403 BRAZIL: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 404 BRAZIL: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 405 BRAZIL: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 406 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 407 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 408 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 409 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 410 REST OF LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
TABLE 411 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
TABLE 412 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM,  2021–2028 (USD MILLION)
TABLE 413 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 414 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 415 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 416 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 417 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY END USER, 2021–2028 (USD MILLION)
TABLE 418 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
TABLE 419 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 420 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
TABLE 421 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
TABLE 422 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY FORM,  2021–2028 (USD MILLION)
TABLE 423 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 424 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 425 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 426 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 427 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 428 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 429 MIDDLE EAST: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 430 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 431 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 432 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY SOURCE,  2021–2028 (USD MILLION)
TABLE 433 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 434 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 435 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 436 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 437 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
TABLE 438 AFRICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 439 AFRICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 440 AFRICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
TABLE 441 AFRICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
TABLE 442 AFRICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA,  2021–2028 (USD MILLION)
TABLE 443 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
TABLE 444 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
TABLE 445 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2021–2028 (USD MILLION)
TABLE 446 RESEARCH ANTIBODIES AND REAGENTS MARKET: INTENSITY OF COMPETITIVE RIVALRY
TABLE 447 COMPANY FOOTPRINT ANALYSIS
TABLE 448 PRODUCT FOOTPRINT ANALYSIS
TABLE 449 REGIONAL FOOTPRINT ANALYSIS
TABLE 450 RESEARCH ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 451 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 452 RESEARCH ANTIBODIES AND REAGENTS MARKET: PRODUCT LAUNCHES (2020−2023)
TABLE 453 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEALS (2020−2023)
TABLE 454 RESEARCH ANTIBODIES AND REAGENTS MARKET: OTHER DEVELOPMENTS (2020−2023)
TABLE 455 ABCAM PLC: BUSINESS OVERVIEW
TABLE 456 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
TABLE 457 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
TABLE 458 MERCK KGAA: BUSINESS OVERVIEW
TABLE 459 BD: BUSINESS OVERVIEW
TABLE 460 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
TABLE 461 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
TABLE 462 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
TABLE 463 DANAHER: BUSINESS OVERVIEW
TABLE 464 LONZA.: BUSINESS OVERVIEW
TABLE 465 GENSCRIPT: BUSINESS OVERVIEW
TABLE 466 REVVITY: BUSINESS OVERVIEW
TABLE 467 ILLUMINA, INC.: BUSINESS OVERVIEW
TABLE 468 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW
TABLE 469 FUJIREBIO: COMPANY OVERVIEW
TABLE 470 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
TABLE 471 OMEGA BIO-TEK, INC.: COMPANY OVERVIEW
TABLE 472 DOVETAIL GENOMICS: COMPANY OVERVIEW
TABLE 473 ATLAS ANTIBODIES AB: COMPANY OVERVIEW
TABLE 474 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
TABLE 475 SANTA CRUZ BIOTECHNOLOGY, INC.: COMPANY OVERVIEW
TABLE 476 JACKSON IMMUNORESEARCH INC.: COMPANY OVERVIEW
TABLE 477 PROTEINTECH GROUP, INC.: COMPANY OVERVIEW
TABLE 478 ICL, INC.: COMPANY OVERVIEW
TABLE 479 SOUTHERNBIOTECH: COMPANY OVERVIEW
LIST OF FIGURES (51 FIGURES)
FIGURE 1 RESEARCH ANTIBODIES AND REAGENTS MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARIES
FIGURE 4 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) FOR 2022
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS METHODOLOGY
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
FIGURE 8 MARKET VALIDATION FROM PRIMARY SOURCES
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 RESEARCH ANTIBODIES AND REAGENTS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
FIGURE 12 DATA TRIANGULATION METHODOLOGY
FIGURE 13 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,  2023 VS. 2028 (USD MILLION)
FIGURE 14 RESEARCH ANTIBODIES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 RESEARCH REAGENTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 16 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY,  2023 VS. 2028 (USD MILLION)
FIGURE 17 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION)
FIGURE 18 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER,  2023 VS. 2028 (USD MILLION)
FIGURE 19 GEOGRAPHIC SNAPSHOT OF RESEARCH ANTIBODIES AND REAGENTS MARKET
FIGURE 20 RISING FUNDING INVESTMENTS IN LIFE SCIENCES RESEARCH TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
FIGURE 21 PROTEOMICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 23 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 24 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
FIGURE 25 RESEARCH ANTIBODIES AND REAGENTS MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES
FIGURE 26 RESEARCH ANTIBODIES AND REAGENTS MARKETS: SUPPLY SIDE ANALYSIS
FIGURE 27 REVENUE SHIFT AND REVENUE GROWTH
FIGURE 28 RESEARCH ANTIBODIES AND REAGENT MARKET: PATENT ANALYSIS
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESEARCH ANTIBODY & REAGENT PRODUCTS
FIGURE 30 BUYING CRITERIA FOR PRODUCTS, BY END USER
FIGURE 31 APPLICATION OF ANTIBODIES IN DRUG DEVELOPMENT PROCESS
FIGURE 32 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT
FIGURE 33 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT
FIGURE 34 KEY DEVELOPMENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET
FIGURE 35 MARKET SHARE ANALYSIS FOR OVERALL MARKET, BY KEY PLAYER (2022)
FIGURE 36 RESEARCH ANTIBODIES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2022)
FIGURE 37 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2020–2022)
FIGURE 38 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (2022)
FIGURE 39 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022)
FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022)
FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022)
FIGURE 43 BD: COMPANY SNAPSHOT (2022)
FIGURE 44 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
FIGURE 46 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022)
FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022)
FIGURE 48 LONZA: COMPANY SNAPSHOT (2022)
FIGURE 49 GENSCRIPT: COMPANY SNAPSHOT (2022)
FIGURE 50 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)